Shares in Eli Lilly & Co (LLY) jumped 13% after the drugmaker reported that the results of a late stage study of its breast cancer therapy Verzenio met the primary endpoint of “significantly” reducing its recurrence in early stages.The stock surged 13% to $159.40 in early market trading after the drugmaker disclosed positive results of its Verzenio therapy in a Phase 3 study of 5,637 people whose early breast cancer is at a high risk of recurrence. Despite progress in the treatment of breast cancer, about 30% of people diagnosed with early breast cancer are at risk of their cancer …read more
Source:: Yahoo Finance
